FDA Questions Risk-Benefit of Ariad's Cancer Drug
By Mari Serebrov
Monday, March 19, 2012
WASHINGTON Ariad Pharmaceuticals Inc. will have a lot on the line Tuesday when an FDA advisory committee takes a hard look at the data for its sarcoma drug Taltorivc. But for the FDA, it all comes down to one question do the risks outweigh the benefits?
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.